<?xml version='1.0' encoding='utf-8'?>
<document id="27473523"><sentence text="Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features."><entity charOffset="0-8" id="DDI-PubMed.27473523.s1.e0" text="Tyrosine" /><entity charOffset="40-49" id="DDI-PubMed.27473523.s1.e1" text="Rapamycin" /><pair ddi="false" e1="DDI-PubMed.27473523.s1.e0" e2="DDI-PubMed.27473523.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27473523.s1.e0" e2="DDI-PubMed.27473523.s1.e1" /></sentence><sentence text="The development of multiple vascular endothelial growth factor- and mammalian target of rapamycin-targeted therapies in advanced renal cell carcinoma has resulted in significant clinical benefit"><entity charOffset="88-97" id="DDI-PubMed.27473523.s2.e0" text="rapamycin" /></sentence><sentence text=" However, the availability of multiple treatment options has led to a more complicated clinical decision-making process" /><sentence text=" Prognostic factors have been incorporated into the inclusion criteria for pivotal clinical trials and have thus provided some guidance regarding the selection and sequencing of therapy" /><sentence text=" Even within a given patient risk group and particular line of therapy, questions remain regarding the optimal choice of a targeted agent" /><sentence text=" The present review provides a practical, clinician-oriented assessment of pharmacologic factors that should be considered when a receptor tyrosine kinase or mammalian target of rapamycin kinase inhibitor is used to treat patients with advanced or metastatic renal cell carcinoma"><entity charOffset="139-147" id="DDI-PubMed.27473523.s6.e0" text="tyrosine" /><entity charOffset="178-187" id="DDI-PubMed.27473523.s6.e1" text="rapamycin" /><pair ddi="false" e1="DDI-PubMed.27473523.s6.e0" e2="DDI-PubMed.27473523.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27473523.s6.e0" e2="DDI-PubMed.27473523.s6.e1" /></sentence><sentence text=" Although these 2 classes of agents have different mechanisms of action, they are metabolized by similar pathways, resulting in broadly similar pharmacokinetic and drug-drug interaction profiles" /><sentence text=" To further individualize therapy and optimize clinical benefit, an enhanced understanding of the key pharmacologic features that differentiate these agents is important" /><sentence text="" /></document>